Johns Hopkins POC-IT: Point of Care Information Technology [Home]
HIV Guide
 Zambia HIV National Guidelines
 


Introduction  

HIV Counseling and Testing  

Sexually Transmitted Infections (STIs)  

General Principles of Antiretroviral Therapy for Chronic HIV Infection in Adults and Adolescents  

When to Start ARV Therapy for Chronic HIV Infection in Adults and Adolescents  

Initial Regimen for ARV Therapy  

Adherence  

Baseline evaluation and Monitoring  

Calculations: Ideal Body Weight, Body Mass Index and Creatinine Clearance  

ARV Therapy for Individuals with Tuberculosis Co-Infection  

Adverse Effects and Toxicity  

Immune Reconstitution Inflammatory Syndrome (IRIS)  

Changing or Stopping ART  

Treatment Failure  

Stopping ARV Therapy  

Post Exposure Prophylaxis  

Cotrimoxazole Prophylaxis  

WHO Staging in Adults and Adolescents  

Nutrition Care and Support  

Palliative Care in HIV and AIDS  

 Guide Editors
 Editor In Chief
    Joel E. Gallant, MD, MPH

Pharmacology Editor
    Paul Pham, PharmD, BCPS

Zambia Guideline Team
   Peter Mwaba MMed PhD FRCP
   Alywn Mwinga MMed
   Isaac Zulu MMed MPH
   Velepie Mtonga MMed
   Albert Mwango MBChB
   Jabbin Mulwanda MMed FCS
 

 

 

Drugs>Antimicrobial Agents>
Home PageEmail this module to a friend

Cephalexin

Pham P and Bartlett JG
03-15-2008

  • Available formulation in Zambia: Capsule: 250 mg, 500 mg. Powder for Suspension: 125 mg/5mL, 250 mg/5mL.
  • First generation cephalosporin that can be used as alternative to PCN for treatment of skin and soft tissue infections.
  • Usual adult dose: 250-500 mg every 6 hours
  • Pediatric dose: 25-50 mg/kg divided q6h

REFERENCES

Zambia Information Author: Paul A. Pham, Pharm. D.

INDICATIONS

FDA

  • Osteomyelitis
  • Otitis media
  • Streptococcal pharyngitis
  • Prostatitis (not a first line agent)
  • Respiratory infections
  • Skin and skin structure infections
  • Urinary tract infections
NON-FDA APPROVED USES

  • Furuncle/Carbuncle
  • Impetigo
  • Cellulitis/Erysipelas
  • Folliculitis
  • Bacterial Cystitis, Acute, Uncomplicated
  • Mastitis

FORMS

brand 
name
 
generic 
Mfg 
brand 
forms
 
cost* 
Panixine DisperdoseCephalexinRanbaxyPO
tab
125mg
$0.40
      PO
tab
250mg
$0.80
KeflexCephalexin~Advantus PharmPO
cap
250mg
$0.70
      PO
cap
500mg
$1.50
      PO
susp
125mg/5mL
$0.45 per 5mL
      PO
susp
250mg/5ml
$0.78 per 5ml

*Prices represent cost per unit specified and are representative of "Average Wholesale Price" (AWP). AWP Prices were obtained and gathered by Lakshmi Vasist Pharm D using the Red Book, manufacturer's information, and the McKesson database.

^Dosage is indicated in mg unless otherwise noted.

USUAL ADULT DOSING

Mild to moderate infections: 250 mg PO qid. Severe infections: 500 mg PO qid. Mild skin infections, Streptococcal pharyngitis and uncomplicated cystitis: consider 500mg PO q12h.

RENAL DOSING

DOSING FOR GLOMERULAR FILTRATION OF 50-80

Usual dose

DOSING FOR GLOMERULAR FILTRATION OF 10-50

0.25Gm-1.0Gm q8-12h

DOSING FOR GLOMERULAR FILTRATION OF <10 ML/MIN

0.25Gm-1Gm q24-48h

DOSING IN HEMODIALYSIS

0.25Gm-1Gm q24h plus 0.25-1.0 Gm post-dialysis

DOSING IN PERITONEAL DIALYSIS

250 mg tid

DOSING IN HEMOFILTRATION

No data. Consider 1Gm q12h .

ADVERSE DRUG REACTIONS

COMMON

  • Generally well tolerated
OCCASIONAL

  • Allergic reactions (eosinophilia)
  • Diarrhea and C. difficile  colitis
  • Positive Coombs' test (without hemolytic anemia)
RARE

  • Drug fever
  • Neutropenia and thrombocytopenia
  • Hepatitis
  • Anaphylaxis reaction
  • CNS: convulsions (high dose with renal failure), confusion, disorientation, and hallucinations.
  • Hemolytic anemia (theoretical, case reports with ceftriaxone, cefotetan, cefoxitin, cefamandole, ceftazidime, and cefalothin)

DRUG INTERACTIONS

Probenecid: increase in cephalosporin serum concentration due to inhibition of tubular secretion by probenecid. No dose adjustment needed, but close monitoring recommended in ESRD.

SPECTRUM

Detailed Spectrum of Activity

PHARMACOLOGY

Pharmacology

COMMENTS

Well absorbed 1st generation cephalosporin with good gram positive coverage and a low price but q6-8h dosing may decrease patient compliance. With the increasing prevalence of community-acquired MRSA soft tissue infections, use of cephalexin for moderate or serious infections should be guided by sensitivity data.

REFERENCES

REFERENCED WITHIN THIS GUIDE


 
Diagnosis
 


Complications of Therapy


Malignancies


Miscellaneous


Opportunistic Infections


Organ System

Drugs
 


Antimicrobial Agents


Antiretrovirals


Miscellaneous

Guidelines
 


Zambia HIV National Guidelines

Management
 


Antiretroviral Therapy


Laboratory Testing


Miscellaneous

Pathogens
 


Bacteria


Fungi


Parasites


Viruses

View All Modules
 
Index
 
 
Contacts    Help    Copyright    Acknowledgments    Abbreviations